
Advances in Cancer Research
- 1st Edition, Volume 168 - December 1, 2025
- Imprint: Academic Press
- Editors: Paul B. Fisher, Kenneth D. Tew
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 3 4 4 8 1 - 7
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 4 4 8 2 - 4
Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an internati… Read more
Purchase options

Advances in Cancer Research series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors
- Provides the latest information on cancer research
- Offers outstanding and original reviews on a range of cancer research topics
- Serves as an indispensable reference for researchers and students alike
Avri Ben-Ze’ev and Arka Saha
2. TBD
Eduardo Nestor Maldonado, Leilei Zhang, Danyelle Townsend and Milagros Junco
3. AEG-1 on Cancer Drug Resistance: From Molecular Insights to Therapeutic Challenges
Seok-Geun Lee, Dong-Chul Kang, Wali Ullah, Hail Kim, Sanghee Han and Minseo Oh
4. Multimodal AI to differentiate tumor progression from treatment effect in glioblastoma
Bijoy Kundu
5. The Role of Epigenetic Modifications in Mediating Cancer Health Disparities
Steven Grant, Dhanvin Yajaman and Dhanush Bearelly
6. In search of a targetable immune profile for acute myeloid leukemia
Gurnit Kaur, Negar Ghaffari, Nagesh Kalakonda, William Grey and Vanessa Marensi
7. Notch signaling in tumorigenesis and maitenance of cancer stem cells
Dong-Chul Kang, Seok-Geun Lee, Ji-Hong Park and Jeong Won Kim
8. Michael Addition Drugs and Cancer
Kenneth D. Tew
9. TBD
Rajagopal Ramesh, Dinesh Babu Somasundaram, Anupama Munshi and Meghna Mehta
- Edition: 1
- Volume: 168
- Published: December 1, 2025
- Imprint: Academic Press
- Language: English
PF
Paul B. Fisher
KT
Kenneth D. Tew
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.